0.700
+0.002
(0.34%)
Real-time:
2:14PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 0.68 - 0.72 |
| 52 week | 0.62 - 1.38 |
| Open | 0.70 |
| Vol / Avg. | 519,306.00/402,036.00 |
| Mkt cap | 13.09M |
| P/E | - |
| Div/yield | - |
| EPS | -1.03 |
| Shares | 18.70M |
| Beta | 1.35 |
| Inst. own | 7% |
Events
Mar 20, 2013
DARA BioSciences at Roth Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -62.86% | -156.17% |
| Return on average equity | -64.96% | -196.51% |
| Employees | 8 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 160, 8601 Six Forks Road
RALEIGH, NC 27615
United States - Map
+1-919-8725578 (Phone)
+1-919-8610239 (Fax)
RALEIGH, NC 27615
United States - Map
+1-919-8725578 (Phone)
+1-919-8610239 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen). As of December 31, 2011, the Company continues to have an internal clinical development program for its two drug candidates, which cleared investigational new drug applications from the Food and Drug Administration (FDA), KRN5500 and DB959. Its KRN5500 is a non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer. DB959 is a drug candidate for the treatment of type II diabetes and dyslipidemia. On January 17, 2012, the Company acquired Oncogenerix, Inc.
Officers and directors
| Haywood D. Cochrane Jr. | Chairman of the Board | |
| Christopher G. Clement | President, Chief Operating Officer, Director | |
| David J Drutz M.D. | Chief Executive Officer, Chief Medical Officer, Director | |
| David L Tousley | Acting Chief Financial Officer | |
| Ann A. Rosar | Chief Accounting Officer | |
| Timothy J. Heady | Director | |
| Stephen O Jaeger | Director | |
| Paul J. Richardson | Director | |
| Gail F Lieberman | Independent Director |